SAMSUNG-ELECTRONICS
9.9.2021 10:02:12 CEST | Business Wire | Press release
Samsung Electronics Co., Ltd., a world leader in advanced semiconductor technology, today announced that four of its System LSI products received product carbon footprint label certification from the Carbon Trust, the first of Samsung’s logic chips to do so.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210909005409/en/
Having received the semiconductor industry’s first carbon footprint accreditation for memory chips from the Carbon Trust in 2019, Samsung has now broadened its ESG (Environmental, Social, and Governance) spectrum with this global recognition of ‘eco-friendly’ logic chips. Samsung also grabbed the industry’s first triple Carbon Trust Standard for Carbon, Water and Waste in June 2021.
The Carbon Trust is an independent and expert partner of organizations around the world that advises businesses on their opportunities in a sustainable, low carbon world. The Carbon Trust also measures and certifies the environmental footprint of organizations, supply chains and products.
Of the various certification categories of the Carbon Trust, Samsung’s System LSI products received the CO2 Measured product carbon footprint label. The label certifies the chip’s carbon footprint, which informs consumers of the impact that the product and its manufacturing process have on the environment.
Receiving the CO2 Measured label is a critical first step for carbon reduction, since it verifies the current carbon emissions of the product with globally recognized specifications (PAS 2050), which Samsung can use as a benchmark to measure future carbon reductions.
Correctly measuring the carbon footprint of a product requires extensive effort and time. It involves calculating the amount of carbon emitted from fabricating raw subsidiary materials and transporting the product, as well as the carbon emission from using electricity, water, and gas. The hundreds of fabrication processes needed to make a semiconductor chip adds to the complication.
“We’re pleased to have worked with Samsung on this step in its sustainability journey,” said Hugh Jones, managing director at the Carbon Trust Advisory. “The Carbon Trust’s Carbon Measured certification is a clear and credible indicator for consumers that the carbon footprint of these products have been independently verified, as well as a baseline for Samsung to compare against as they work towards reducing their emissions in the future.”
The four products to receive certification include a variety of Samsung’s System LSI chips, from mobile processors to image sensors. The Exynos 2100, one of the four products to receive certification, is a high-performance mobile processor built with the most advanced 5-nanometer (nm) extreme ultra-violet (EUV) process node. The 0.7-micrometer (μm)-pixel image sensor ISOCELL HM2, DTV SoC (S6HD820), and TCON (S6TST21) also received certification by the Carbon Trust.
Including the four chips, Samsung has so far received certifications for fourteen of its semiconductor products from the Carbon Trust.
“We are thrilled to be globally acknowledged for our eco-friendly efforts,” said Seong-dai Jang, senior vice president and head of DS Corporate Sustainability Management Office at Samsung Electronics. “We will continue to fulfill our carbon reduction goals and expand our efforts to a wider range of eco-friendly, high-performance products to meet the global standards for a sustainable future.”
Exynos 2100
Based on 5nm EUV process technology, the Exynos 2100 is Samsung’s first 5G-integrated flagship mobile processor for premium mobile devices. The Exynos 2100 performs up to 26-trillion-operations-per-second (TOPS) with more than twice the power efficiency than the previous generation.
ISOCELL HM2
The ISOCELL HM2 is a 0.7μm-pixel image sensor that opened up the market for ultra-high resolutions. The 108MP-sensor is around 15 percent smaller than the 0.8μm-based predecessors, and reduces the height of the camera module by 10 percent, while featuring faster autofocus, nine-pixel binning and 3x lossless zoom.
DTV SoC (S6HD820)
Samsung’s DTV SoC (S6HD820) is an essential component in television as picture quality evolves from 4K to 8K standard. The DTV SoC’s NPU (neural processing unit) allows AI technology to improve picture quality and audio processing.
TCON (S6TST21)
A TCON takes video data from the DTV SoC and converts it according to the demands of the DDI (Display Driver IC). The data transmission speed of the TCON is important when it comes to quickly transmitting high-resolution video data to the DDI. Samsung’s TCON (S6TST21) integrates two 8K 60-hertz (Hz) chips to minimize energy loss.
About Samsung Electronics Co., Ltd.
Samsung inspires the world and shapes the future with transformative ideas and technologies. The company is redefining the worlds of TVs, smartphones, wearable devices, tablets, digital appliances, network systems, and memory, system LSI, foundry and LED solutions. For the latest news, please visit the Samsung Newsroom at http://news.samsung.com .
View source version on businesswire.com: https://www.businesswire.com/news/home/20210909005409/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Incyte Announces Positive CHMP Opinion for Zynyz® (retifanlimab) for First-Line Treatment of Advanced Squamous Cell Carcinoma of the Anal Canal (SCAC)30.1.2026 15:29:00 CET | Press release
Pending the European Commission decision, Zynyz® (retifanlimab) in combination with carboplatin and paclitaxel (platinum-based chemotherapy) will be the first PD-1 immunotherapy treatment for patients with advanced squamous cell carcinoma of the anal canal (SCAC) in EuropeGlobally, the prevalence of SCAC is estimated at around 1 or 2 cases per 100,000 people, with a higher incidence in women than in men1,2,3The Committee for Medicinal Products for Human Use (CHMP) positive opinion is based on data from the Phase 3 POD1UM-303/InterAACT2 trial which showed patients with advanced SCAC achieved significantly improved progression-free survival with Zynyz in combination with carboplatin and paclitaxel as a first-line treatment4 Incyte (Nasdaq:INCY) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has issued a positive opinion recommending the approval of Zynyz® (retifanlimab) in combination with carboplatin and paclitaxel (
Mediawan to Acquire The North Road Company, Creating a New Global Independent Content Platform30.1.2026 13:32:00 CET | Press release
Mediawan, the leading independent European studio led by Pierre-Antoine Capton, co-founded by Capton, Xavier Niel and Matthieu Pigasse, today announced the signing of an agreement to acquire The North Road Company (“North Road”), the preeminent independent U.S.-based studio founded by Peter Chernin. The combination creates one of the world’s largest independent studios with major creative hubs in the five continents and capabilities spanning all genres, formats and audiences. Together, Mediawan and North Road will have a stronger ability to accelerate the development of powerful IP, foster fresh creative synergies through format adaptations and co-production opportunities, and deliver ever greater value to viewers, talent and partners worldwide. The acquisition brings together two of the most dynamic independent studios in the sector with world-class creative talent, premium IP, and the scale to deliver content at the highest level. In an industry undergoing significant consolidation,
BrightSign Powers Intelligent Signage Experiences at ISE 202630.1.2026 09:00:00 CET | Press release
The Latest Players and AI Capabilities Drive Captivating, Personalized, and Interactive Signage With more industries embracing the power of visual storytelling, BrightSign, the provider of the most advanced, capable, and trusted digital media players and operating system, will showcase the latest developments in digital signage technology at ISE 2026 in Barcelona, Spain from February 3-6, 2026. BrightSign’s latest innovations come to life at booth #4S-150 through interactive real-world demos featuring retail, QSR, transportation, and corporate use cases. Visitors can test new AI-powered object detection capabilities of BrightSign players, allowing them to pick up an object and see the content on the screen respond immediately. Booth activations will be powered by BrightSign’s reliable platform including bsn.Control, BrightSignOS™, brightAuthor connected, and its global partner ecosystem. “In today’s immersive, personalized and visual world, the stakes have never been higher for powerfu
Candela Ushers in a New Era of Aesthetic Innovation at IMCAS Paris With the Launch of the Glacē™ System30.1.2026 08:30:00 CET | Press release
Iconic Vbeam® Pro and Matrix™ Systems showcased ahead of broader commercial availability Candela, a global leader in energy-based aesthetic technologies, today announced the European launch of the Glacē™ System, a facial treatment platform that signals a bold new chapter for the company and the future of aesthetic medicine. In addition to the launch of the Glacē System, Candela will also showcase its Matrix system for radiofrequency-based skin renewal and its iconic Vbeam® Pro vascular treatment platform at IMCAS 2026. Both Matrix and VBeam Pro platforms are currently available in select EMEA markets and are expected to be comprehensively launched shortly, further strengthening Candela’s leadership in the energy-based device market. Unveiled at the IMCAS World Congress 2026, these launches underscore Candela’s continued commitment to delivering innovative, science-backed treatment solutions for high-demand patient needs. Candela leads the industry in clinical efficacy and safety, suppo
Merz Therapeutics Appoints Dan Staner as President, Region Europe30.1.2026 08:00:00 CET | Press release
Merz Therapeutics today announced the appointment of Dan Staner as President, Region Europe, effective February 1, 2026. In this role, Dan will oversee the company’s European business and drive regional growth. Dan will report directly to Merz Therapeutics Chief Executive Officer, Stefan König, and will join the Therapeutics Executive Team. His appointment reflects the company’s continued commitment to strengthening its leadership capabilities and accelerating its growth strategy across key European markets. “Dan brings a strong track record of building and scaling biopharmaceutical businesses across Europe,” said Stefan König, CEO of Merz Therapeutics. “His deep commercial, strategic, and regional leadership experience will be instrumental in advancing our growth ambitions, expanding patient access to our therapies, and further strengthening our presence in Europe. We are very pleased to welcome Dan to Merz Therapeutics.” Throughout his career, Dan has held senior leadership roles i
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
